020 7713 0990
SITE MAP
- HO 2010 Best practice in lymphoma specific disease index
- HO 2010 Best practice in lymphoma diagnosis and reporting
- HO 2010 Facilities for the treatment of adults with haematological malignancies
- HO 2010 Diagnosis of PTLD
- HO 2010 Management of PTLD
- HO 2009 MGUS and M Proteins
- HO 2009 plasmacytomas
- HO A 2008 fungal infection
- HO 2007 primary CNS lymphoma (PCNSL) and primary intra-ocular lymphoma (PIOL)
- HO A 2007 BCR-ABL-positive Chronic Myeloid Leukaemia
- HO 2007 Amendment polycythaemia/ erythrocytosis
- HO A 2006 Waldenström’s Macroglobulinaemia
- HO A 2006 imaging in myeloma
- HO A 2006 Multiple Myeloma 2005
- HO 2006 Central Venous Access Devices In Adults
- HO 2005 polycythaemia/ Erythrocytosis
- HO A 2004 AL Amyloidosis
- HO 2002 infections absent dysfunctional spleen
- HO A 2000 Hairy Cell Leukaemia
- GH 2010 thrombocytosis
- GH 2010 Significant haemoglobinopathies
- GH 2009 aplastic anaemia
- GH 2008 point-of-care testing
- GH 2007 Amendment polycythaemia/erythrocytosis
- GH 2005 malaria
- GH 2005 Polycthaemia / Erythrocytosis
- GH A 2004 Hereditary Spherocytosis
- HT 2004 Diagnosis dvt outpatients D-dimer assays
- GH 2003 Acute Painful Crisis Sickle Cell
- HT 2010 Prophylaxis in haemophilia
- HT 2010 Testing for Heritable Thrombophilia
- HT 2009 Disseminated Intravascular Coagulation
- HT 2008 therapeutic products haemophilia
- HT 2008 assessment of bleeding risk surgery
- HT 2007 oral anticoagulants dental surgery
- HT 2007 Safety indicators oral anticoagulant
- HT 2006 Vena Cava Filters
- HT 2006 use and monitoring of heparin
- HT 2006 heparin induced thrombocytopenia
- HT 2005 oral third edition
- HT 2007 INR in patients not on vitamin K antagonists
- HT A 2005 venous thrombosis travel info travelers
- HT 2003 Guidelines on Fibrinogen Assays
- HT A 2003 Thrombotic Microangiopathic Haemolytic Anaemias
- BT 2010 Appendices validation and qualification
- BT 2009 The Administration of Blood Components
- BT 2009 FMH
- BT 2007 Amendment FFP and cryo
- BT 2007 Amendment neonates older children
- BT 2007 policies alternatives allogeneic
- BT A 2006 Management Massive Blood Loss
- BT 2006 prophylactic anti-D
- BT 2006 blood grouping antibody test pregnancy
- BT 2006 Information Technology
- BT 2010 Validation and qualification
- BT 2004 compatibility procedures
- BT 2004 Fresh Frozen Plasma, etc
- GH A 2003 idiopathic thrombocytopenic purpura
- BT 2004 Neonates and Older Children
- BT 2003 Use Of Platelet Transfusions
- BT A 1997 autologous transfusion. II.
- BT 2001 clinical use red cell tranfusion
- BT A 1996 gamma irradiation
- HT 2006 Amendment management heparin induced thrombocytopenia
- BT A 2000 blood bank computing
- BT A 1999 FMH
- BT A 1999 Addendum blood group antibody test pregnancy
- BT A 1999 administration blood components
- BT A 1998 leucocyte depleted blood components
- BT 2010 irradiated blood components
- BT A 1998 blood cell separators
- BT A 1996 compatibility procedures
- BT A 1996 gamma irradiation of blood components
- BT A 1995 validation screening cross-matching
- BT A 1994 transfusion of infants and neonates
- BT A 1993 autologous transfusion I
- BT A 1992 platelet transfusion
- BT A 1992 fresh frozen plasma
- BT 1990 A microplate techniques
- BT 1990 A hospital blood bank documentation
- BT 1988 A massive blood loss
- BT 1987 A compatibility testing
- GH A 2003 acquired aplastic anaemia
- GH A 2003 Erratum acquired aplastic anaemia
- GH A 2002 Immunophenotyping Leukaemia Lymhoproliferative
- GH A 2000 Genetic Haemochromatosis
- GH A 1999 flow cytometric CD34+ stem cells
- GH A 1998 haemoglobinopathies
- GH A 1997 malaria
- GH A 1997 enumeration CD4+ T lymphocytes
- GH A 1996 leucocyte monoclonal antibodies
- GH A 1996 cytology etc
- BT A 1990 blood separators
- GH A 1994 Cobalamin and folate deficiency
- GH A 1988 Haemoglobinopathy screening
- HT 2011 Travel and thrombosis
- HT 2005 outpatient management deep venous thrombosis
- HT A 2005 patient self-testing mngmt oral anticoagulation
- HT A 2003 Thrombophilia: patients relatives
- HT 2001 Recommendation for patient self-management or oral anticoagulation
- HT 2001 Investigation and management of heritable thrombophilia
- HT 1996 Guidelines on the prevention, investigation and management of thrombosis associated with pregnancy
- HT 1998 oral anticoagulation third edition
- GH 2010 Immune Thrombocytopenia, ITP
- HO A 2006 Acute Myeloid Luekaemia
- HO A 2005 Position Statement Bortezomib Multiple Myeloma
- HO A 2004 Chronic Lymphocytic Leukaemia
- HO A 2004 plasmacytoma
- HO A 2003 myelodysplastic syndromes
- HO A 2003 Colony Stimulating Factors
- HO A 2003 Thalidomide in multiple myeloma: Current status and future prospects
- HO A 2003 Bisphosphonates in myeloma
- HO A 2003 non-Hodgkin's lymphoma
- HO A 2003 Position paper Rituximab Non-Hodgkin's Lymphoma
- HO A 2002 Position paper Imatinib chronic myeloid leukaemia
- HO A 2001 multiple myeloma
- HO A 2001 Waldenstrom's Macroglobulinaemia
- HO A 2000 Position paper Anagrelide
- HO A 1995 facilities for the care of
- HO A 1997 central venous lines
- HT A 2002 Investigation mngmt neonatal h and t
- HT 2000 Inv mngmt antiphospholipid syndrome
- BT A 1994 collection bone marrow peripheral stem cell
- BT A 1990 maximum surgical blood order schedule
- HO A 2006 Consent for chemotherapy
- HO 2010 Management of Multiple myelomoa
- H0 2010 Supportive care multiple myeloma
- HT A 2000 Anticoagulant therapy and referral form
- HT A 1995 Consensus report: Guidelines for the use of thrombolytic therapy
- HT A 1994 haemorrhagic disorders pregnancy
- HT A 1993 Audit anticoagulation
- HT A 1993 thrombosis and pregnancy
- HT A 1993 use monitoring heparin second revision
- HT A 1991 lupus anticoagulant
- HT A 1990 oral anticoagulation 2nd edition
- BT 2009 Summary ammendments FMH
- BT A 1996 Antenatal serology testing
- BT A 1993 Evaluation biodepleted plasmas
- BT A 1988 autologous transfusion
- BT A 1988 platelet function testing
- GH A 1994 thalassaemia alpha and beta trait
- BT 2005 FFP amedment storage
- GH A 1994 fetal diag globin gene disorders
- GH A 1994 Immunophenotyping acute leukaemias
- GH A 1994 Immunphenotyping chronic lymphoprolif
- WIP GH B12 and Folate
- GH 2011 Hereditary spherocytosis
- WIP HT antiphospholipid syndrome
- WIP HT platelet abnormalities
- HT 2011 platelet function
- WIP HT Warfarin, patients on
- WIP HT Heparin induced thrombocy
- WIP HT inhibitors haemoph
- WIP BT Acute transfusion reactions
- WIP HO al amyloidosis
- WIP HO haem malig and ITU
- HO 2011 Follicular lymphoma
- HT 2010 neonatal fetus haemophilia
- HT 2010 VTE Children
- BT 2005 neonate paeds amendment
- WIP HT factor assays
- WIP HT venous thrombosis unusual sites
- HO 2009 thrombocytosis
- WIP HO Cutaneous T-cell lymphoma
- WIP HO GvHD
- HO 2011 T-cell
- WIP GH Functional iron
- WIP GH Acute chest
- WIP GH Malaria update 2011
- WIP HT Monitoring antiocag
- HT 2011 warfarin
- GH 2011 ATG Urgent addendum
- WIP HT reversal anticoag
- WIP HO CLL
- WIP HO mantle cell
- WIP HO MDS
- WIP HO Waldenstrom
- WIP HO consent
- WIP BT precompatability
- WIP BT Blood component critical care
- WIP BT red cells critical care
- WIP BT neonates older children
- WIP BT IT in transfusion
- WIP BT mngmt anaemia preop
- WIP GH myelofibrosis
- WIP GH acute painful crisis sickle
- GH 2011 UK Iron Deficiency in preganacy
- HO 2011 prevention and treatment of infection in patients with an absent or dysfunctional spleen
- HO 2012 Hairy Cell Leukaemia
- BT A 2010 Appendices Validation and Qualification
